TELA Bio, Inc. Appoints Roberto Cuca as Chief Financial Officer
September 27, 2021 at 07:00 am EDT
Share
TELA Bio, Inc. announced the appointment of Roberto Cuca as Company's Chief Financial Officer. As COO and CFO, Roberto Cuca will lead the execution of the Company's business plan and manage the Company's finances. He will report directly to President and Chief Executive Officer, Antony Koblish. Roberto Cuca joins the TELA team with over 25 years of experience in relevant operational and finance positions within the healthcare industry. Most recently, Mr. Cuca served as Chief Financial Officer of OraSure Technologies where he led the finance and IT functions since joining in 2018. Prior to that time, Mr. Cuca served as Senior Vice President and Chief Financial Officer of Trevana, Inc.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
